madman
Super Moderator
Too late to the game!
Proprietary formulation throwing in the DHEA LOL!
Maximus T protocol (EC + pregnenolone) is where it's been at.
Dr. Cam has you covered and a more cost effective protocol to boot!
finance.yahoo.com
MOJO to be offered as an Oral Dissolvable Tablet (ODT) marketed to younger male demographic as an alternative to PRIME Testosterone Replacement Therapy (TRT)
Dallas, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss and hormone replacement therapies, is pleased to announce the development of proprietary formulations of Enclomiphene Citrate, Pregnenolone and Dehydroepiandrosterone (DHEA) in an Oral Dissolvable Tablet (ODT) aimed at restoring hormonal balance and naturally increasing testosterone levels in men. The new compounded product will be named “MOJO” and sold exclusively on MangoRx’s website on a subscription basis at a price of $199 per month.
MOJO represents the groundbreaking advancement in addressing male hormonal imbalances, particularly hypogonadism (low testosterone) through this unique and powerful formulation and will be offered as an alternative to the Company’s existing FDA approved oral Testosterone Replacement Therapy (TRT), PRIME by MangoRx, powered by Kyzatrex®.
MOJO’s key components and therapeutic benefits include the following innovative compounded ingredients:
"Our new Enclomiphene citrate formulation, MOJO, represents a significant breakthrough in the treatment of male hormonal imbalances," said Jacob Cohen, Co-Founder and CEO of MangoRx. "With our most recent launch of PRIME by MangoRx, powered by Kyzatrex®, MOJO is intended to be complementary to PRIME and marketed to those in the earlier stages of experiencing secondary hypogonadism, or low testosterone. This product underscores our commitment to advancing the standard of care in male hormonal therapy and improving the lives of our patients."
Low testosterone is a widespread condition that affects millions of men globally, presenting significant challenges to overall health and quality of life. Traditional treatments often present undesirable side effects or compromise fertility. MOJO leverages and features the synergistic effects of Enclomiphene citrate, DHEA, and Pregnenolone to address these issues effectively and safely, setting a new standard in male hormonal therapy.
The market for treatments addressing male hormonal imbalances is substantial and growing. In the United States alone, millions of men suffer from hypogonadism, with the global market for testosterone replacement therapy projected to reach $2.9 billion by 2032 according to Allied Market Research. MangoRx’s new formulation, MOJO, which is anticipated to be launched on the Company’s website before the end of the 2nd quarter, is well-positioned to capture a significant share of this market, offering a superior alternative to traditional therapies.
Proprietary formulation throwing in the DHEA LOL!
Maximus T protocol (EC + pregnenolone) is where it's been at.
Dr. Cam has you covered and a more cost effective protocol to boot!
MangoRx to Introduce “MOJO” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone Imbalances
MOJO to be offered as an Oral Dissolvable Tablet (ODT) marketed to younger male demographic as an alternative to PRIME Testosterone Replacement Therapy (TRT) Dallas, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on...
MOJO to be offered as an Oral Dissolvable Tablet (ODT) marketed to younger male demographic as an alternative to PRIME Testosterone Replacement Therapy (TRT)
Dallas, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss and hormone replacement therapies, is pleased to announce the development of proprietary formulations of Enclomiphene Citrate, Pregnenolone and Dehydroepiandrosterone (DHEA) in an Oral Dissolvable Tablet (ODT) aimed at restoring hormonal balance and naturally increasing testosterone levels in men. The new compounded product will be named “MOJO” and sold exclusively on MangoRx’s website on a subscription basis at a price of $199 per month.
MOJO represents the groundbreaking advancement in addressing male hormonal imbalances, particularly hypogonadism (low testosterone) through this unique and powerful formulation and will be offered as an alternative to the Company’s existing FDA approved oral Testosterone Replacement Therapy (TRT), PRIME by MangoRx, powered by Kyzatrex®.
MOJO’s key components and therapeutic benefits include the following innovative compounded ingredients:
- Enclomiphene Citrate: A purified isomer of Clomid (Clomiphene Citrate) which has been FDA approved since 1967 and has been proven to be effective in stimulating the body's natural testosterone production, addressing hormonal imbalances at their source.
- DHEA: A precursor hormone that supports overall hormonal balance, DHEA is linked to improvements in energy levels, mood, and general well-being.
- Pregnenolone: Known as the “mother hormone,” Pregnenolone plays a crucial part in the production of other essential hormones and supports cognitive and mental health.
"Our new Enclomiphene citrate formulation, MOJO, represents a significant breakthrough in the treatment of male hormonal imbalances," said Jacob Cohen, Co-Founder and CEO of MangoRx. "With our most recent launch of PRIME by MangoRx, powered by Kyzatrex®, MOJO is intended to be complementary to PRIME and marketed to those in the earlier stages of experiencing secondary hypogonadism, or low testosterone. This product underscores our commitment to advancing the standard of care in male hormonal therapy and improving the lives of our patients."
Low testosterone is a widespread condition that affects millions of men globally, presenting significant challenges to overall health and quality of life. Traditional treatments often present undesirable side effects or compromise fertility. MOJO leverages and features the synergistic effects of Enclomiphene citrate, DHEA, and Pregnenolone to address these issues effectively and safely, setting a new standard in male hormonal therapy.
The market for treatments addressing male hormonal imbalances is substantial and growing. In the United States alone, millions of men suffer from hypogonadism, with the global market for testosterone replacement therapy projected to reach $2.9 billion by 2032 according to Allied Market Research. MangoRx’s new formulation, MOJO, which is anticipated to be launched on the Company’s website before the end of the 2nd quarter, is well-positioned to capture a significant share of this market, offering a superior alternative to traditional therapies.
